Earnings call transcript: Procept Biorobotics Q1 2026 beats EPS expectations

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

Realty Income (NYSE: O) says it began investing in data centers in late 2023 via a build-to-suit JV with Digital Realty, buying an 80% stake in an up to 48 MW facility. It also formed a hyperscale JV with Cloud Capital, targeting up to $1.4B investment for a 45% stake. Realty Income raised 2024 AFFO guidance to $4.44-$4.45/share and investment outlook to $10B.

Bloomberg reported the US Army plans to buy at least $400 million of AeroVironment counter-drone laser systems, citing a person familiar with the deal. The order would include dozens of LOCUST units that use AI to detect and track small to medium drones and then engage them with a high-energy laser. AeroVironment’s stock rose about 8% on Friday.

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).